down arrow

Cartesian Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8162121045
USD
7.22
-0.14 (-1.9%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

7.137.60

52 Week

5.9820.30
Valuation
Technical
Day's Volume

CASH

297.63 k

Shareholding (Mar 2025)

FII

3.11%

Held by 32 FIIs

DII

74.45%

Held by 17 DIIs

Promoter

6.45%

What does Cartesian Therapeutics, Inc. do?

22-Jun-2025

Cartesian Therapeutics, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry. It currently has no available net sales or profit, a dividend yield of 0.00%, and significant negative debt equity and return on equity metrics.

Overview:<BR>Cartesian Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: Not available<BR>Most recent Net Profit: Not available<BR>Market cap: Micro Cap<BR><BR>Key Metrics:<BR>Industry: Pharmaceuticals & Biotechnology<BR>Dividend Yield: 0.00%<BR>Debt Equity: -999,999.00<BR>Return on Equity: -999,999.00%<BR>Price to Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Cartesian Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of May 4, 2023, Cartesian Therapeutics, Inc. is considered overvalued and risky due to its negative P/E ratio of -6.14, negative EV to EBITDA of -2.42, and a year-to-date return of -42.43%, significantly underperforming the S&P 500's 12.22% return.

As of 4 May 2023, the valuation grade for Cartesian Therapeutics, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its negative P/E ratio of -6.14 and EV to EBITDA of -2.42, which suggest significant challenges in profitability and operational efficiency. Additionally, the absence of a PEG ratio further complicates the valuation picture.<BR><BR>In comparison to its peers, Cartesian Therapeutics is underperforming; for instance, its negative P/E and EV to EBITDA ratios contrast sharply with industry expectations. The stock has significantly lagged behind the S&P 500, with a year-to-date return of -42.43% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued in its current state.

Read More

Is Cartesian Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Cartesian Therapeutics, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -42.43%.

As of 10 September 2025, the technical trend for Cartesian Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the overall bearish signals from the On-Balance Volume (OBV) and Dow Theory on both weekly and monthly time frames. While the MACD shows mildly bullish signals on the weekly and monthly charts, this is overshadowed by the bearish trends in Bollinger Bands and the KST on the monthly. <BR><BR>In terms of performance, Cartesian Therapeutics has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -42.43% compared to the S&P 500's 12.22%, and a 1-year return of -34.04% versus 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • RAW MATERIAL COST(Y) Grown by 200.24% (YoY)
2

Risky - No result in last 6 months

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 265 Million (Micro Cap)

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

61.94

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

-104.85

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
16 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.52%
0%
-23.52%
6 Months
-27.8%
0%
-27.8%
1 Year
-62.53%
0%
-62.53%
2 Years
-65.5%
0%
-65.5%
3 Years
-78.12%
0%
-78.12%
4 Years
-92.24%
0%
-92.24%
5 Years
-91.98%
0%
-91.98%

Cartesian Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Cartesian Therapeutics Hits New 52-Week Low at $5.98 Amidst Declining Performance

Cartesian Therapeutics Hits New 52-Week Low at $5.98 Amidst Declining Performance

Cartesian Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in performance over the past year. The company, with a market capitalization of USD 265 million, faces financial pressures, including rising raw material costs and a lack of reported results, raising concerns about its operational stability.

Read More
Cartesian Therapeutics Hits 52-Week Low at $7.67 Amidst Significant Decline

Cartesian Therapeutics Hits 52-Week Low at $7.67 Amidst Significant Decline

Cartesian Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline from its previous high. The company has struggled with a substantial drop in stock value and has faced challenges such as rising raw material costs and a lack of recent performance reports, raising concerns about its stability.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
39.49%
EBIT Growth (5y)
3.86%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
31.44%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (16.0%)

Foreign Institutions

Held by 32 Foreign Institutions (3.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -99.10% vs 542.31% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 65.63% vs 184.21% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "33.40",
          "chgp": "-99.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.20",
          "val2": "14.50",
          "chgp": "-246.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "36.00",
          "val2": "-1.90",
          "chgp": "1,994.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.90",
          "val2": "9.60",
          "chgp": "65.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-73,191.30%",
          "val2": "426.70%",
          "chgp": "-7,361.80%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 49.62% vs -76.53% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.92% vs -826.84% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "38.90",
          "val2": "26.00",
          "chgp": "49.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.50",
          "val2": "-84.90",
          "chgp": "65.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-54.50",
          "val2": "-155.90",
          "chgp": "65.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.40",
          "val2": "-257.30",
          "chgp": "69.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-786.80%",
          "val2": "-3,323.20%",
          "chgp": "253.64%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.30
33.40
-99.10%
Operating Profit (PBDIT) excl Other Income
-21.20
14.50
-246.21%
Interest
0.00
0.00
Exceptional Items
36.00
-1.90
1,994.74%
Consolidate Net Profit
15.90
9.60
65.63%
Operating Profit Margin (Excl OI)
-73,191.30%
426.70%
-7,361.80%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -99.10% vs 542.31% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 65.63% vs 184.21% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
38.90
26.00
49.62%
Operating Profit (PBDIT) excl Other Income
-29.50
-84.90
65.25%
Interest
0.00
2.10
-100.00%
Exceptional Items
-54.50
-155.90
65.04%
Consolidate Net Profit
-77.40
-257.30
69.92%
Operating Profit Margin (Excl OI)
-786.80%
-3,323.20%
253.64%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 49.62% vs -76.53% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 69.92% vs -826.84% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cartesian Therapeutics, Inc. stock-summary
stock-summary
Cartesian Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."